Pressing regulatory challenges for psychedelic medicine
Amy L. Mcguire, Holly Fernandez Lynch, Lewis A. Grossman, I. Glenn Cohen
Science April 27, 2023 DOI: 10.1126/science.adg1324 (opens in new tab)
Study at a glance
AI-extracted from the abstract| Characteristics | Peer reviewed |
|---|---|
| Keywords | Traditional medicine |
| Citations | 20 |
| Key points | Policy must support generation of evidence on safety and effectiveness. |
Abstract
Policy must support generation of evidence on safety and effectiveness.
Citations in the library
Cited by 16
- Ethnoracial inclusion in clinical trials of psychedelics: a systematic review. EClinicalMedicine August 1, 2024
- Developing an Ethics and Policy Framework for Psychedelic Clinical Care: A Consensus Statement. JAMA Network Open June 3, 2024
- History, Hype, and Responsible Psychedelic Medicine: A Qualitative Study of Psychedelic Researchers. Journal of Bioethical Inquiry October 4, 2024
- From Efficacy to Effectiveness: Evaluating Psychedelic Randomized Controlled Trials for Trustworthy Evidence‐Based Policy and Practice Pharmacology Research & Perspectives April 1, 2025
- A taxonomy of regulatory and policy matters relevant to psychedelic-assisted therapy in Australia Australian & New Zealand Journal of Psychiatry April 16, 2024
and 11 more in the library
Cites 3
- Single-Dose Psilocybin for a Treatment-Resistant Episode of Major Depression. New England Journal of Medicine November 3, 2022
- Psychedelic Drug Legislative Reform and Legalization in the US JAMA Psychiatry December 7, 2022
- Psychedelic-Assisted Psychotherapy—A Systematic Review of Associated Psychological Interventions Frontiers in Psychology June 10, 2022